Guardant Health races to $1.3B in revenue while losses keep widening past $110M a quarter

---

There is a specific kind of growth story that Wall Street loves and that careful readers of financial statements have learned to fear. It looks like Guardant Health's first quarter of 2026. Revenue up 48% to $302 million — the fastest year-over-year growth in five years. A blood test for colorectal cancer screening, Shield, whose revenue grew more than 600% to $41.6 million. A management team raising full-year guidance to $1.30 billion to $1.32 billion. A trailing-twelve-month revenue figure that finally crosses the symbolic billion-dollar line. And, threaded through all of it, the implicit promise: this is the inflection, this is the moment a long-money-losing diagnostics company becomes the franchise its valuation has always assumed it would be.

The trouble is that the same quarter that produced the 48% growth also produced a net loss of $112.1 million. Not a narrowing loss. A widening one — bigger than the $95.2 million the company lost in the same quarter a year earlier. Guardant grew revenue by roughly $98 million year-over-year and managed to lose seventeen million more dollars doing it. That is not the arithmetic of a business approaching profitability. It is the arithmetic of a business buying revenue, and the central question for any investor underwriting GH at today's price is whether the revenue it is buying will ever be worth more than what it costs to acquire.

This is a forensic walk through that question. Not a verdict on whether Shield is a good test — it is, by some measures, a genuinely useful one — but an examination of the distance between the market Guardant is priced for and the income statement it actually reports.

The growth is real; the profitability is theoretical

Start with what is true, because the bull case rests on facts, not fictions. Guardant's oncology business — Guardant360 and the broader liquid-biopsy portfolio — generated $205 million in the quarter, up 36%, on roughly 86,000 tests, a 47% volume increase. The biopharma and data segment added $53 million, up 17%. And screening, the segment the entire equity story now hinges on, grew from $5.7 million a year ago to $41.6 million, as Shield test volume jumped from about 9,000 to about 44,000. Those are not soft numbers. Across three distinct revenue lines, Guardant is selling materially more product than it was a year ago, and the screening line in particular is compounding off a base small enough that triple-digit growth can persist for several more quarters.

But notice what happens when you move two lines down the income statement. The net loss did not shrink as revenue scaled — it grew. The company spent more on sales and marketing to drive Shield adoption, more on research and development, and the incremental gross profit on $98 million of new revenue was not enough to cover the incremental operating spend required to generate it. In a business with real operating leverage, a 48% revenue jump narrows the loss dramatically. In Guardant's first quarter, it didn't. That is the single most important fact in this entire story, and it is the one the headline number is engineered to distract from.

The denominator illusion: a billion in revenue, a quarter-billion in burn

Crossing $1 billion in trailing-twelve-month revenue is the kind of milestone that gets a press release and a slide. It is also a denominator trick. Revenue scale is not the same as financial health, and in Guardant's case the two have moved in opposite directions for years. The company burned $233 million of free cash flow in full-year 2025 — an improvement, to its credit, from $275 million in 2024, but still nearly a quarter of a billion dollars of cash consumed in a single year. In the first quarter of 2026, free cash flow burn was $71 million.

A company that loses $112 million in a quarter and burns $71 million of cash is not self-funding its growth. It is funding that growth with someone else's capital. And the financial statements show exactly whose: in late 2025, Guardant raised $327.3 million in a public equity offering and issued $402.5 million in convertible senior notes. That is over $700 million of fresh capital — dilution and debt — raised to keep the engine running. The screening land grab the bulls celebrate is being financed by selling new shares and borrowing against the future. Every quarter Guardant grows without reaching cash breakeven is a quarter closer to the next raise, and every raise is a transfer of value from existing holders to the new capital that bridges the gap.

Quality of earnings: the stock-comp adjustment that does the heavy lifting

Watch the bridge between GAAP and non-GAAP, because that is where the optimism lives. Guardant, like most growth-stage diagnostics companies, reports adjusted figures that exclude stock-based compensation and the employer payroll taxes attached to it. This is standard practice and entirely legal. It is also, for a company with a persistent GAAP loss, the mechanism by which a money-losing income statement is reframed as a nearly-there one.

Stock-based compensation is not a non-event. It is real compensation, paid in shares, that dilutes existing owners just as surely as a cash salary would have drained the bank account. When a company habitually points investors to a non-GAAP number that adds it back, it is asking them to ignore the cost of the equity it is handing to employees — equity that, quarter after quarter, expands the share count and quietly raises the bar that future profits must clear to deliver per-share value. The $112 million GAAP loss is the honest number. The adjusted figure is the aspirational one. A forensic reader keeps both in view and weights the audited one more heavily, because the adjusted number tells you what management wishes the business looked like, not what it cost shareholders to run it.

Demonstration versus deployment: Shield's clinical asterisk

Here is where the screening thesis meets the science, and the science carries an asterisk that the TAM math tends to skip. Shield won FDA approval as a blood-based colorectal cancer screen, and its pivotal Eclipse study showed colorectal cancer sensitivity of 83.1% — strong enough to clear the bar, useful enough to matter for patients who would otherwise not get screened at all. That is the demonstration, and it is genuine.

The deployment reality is more complicated. The same study reported advanced adenoma sensitivity of just 13.2%. Advanced adenomas are the precancerous lesions that screening, at its best, is supposed to catch before they ever become cancer — the entire prevention rationale of colonoscopy. A test that detects roughly one in eight of them is excellent at finding cancer that already exists and poor at preventing cancer from forming. Independent summaries put Shield's detection of precancerous lesions low enough that the great majority go undetected. By contrast, Exact Sciences' Cologuard Plus reports advanced-adenoma sensitivity in the low-to-mid 40% range and overall CRC sensitivity near 94%. Colonoscopy, the gold standard, remains the first-line choice precisely because it both detects and removes lesions in a single procedure.

None of this makes Shield worthless — convenience drives compliance, and a blood draw a patient will actually accept beats a colonoscopy they keep deferring. But it does complicate the story that Shield will swallow the screening market. The test occupies a real but bounded niche: people who will not do a colonoscopy or a stool test. That niche is large. It is not the entire $1,495-per-test universe the valuation seems to assume.

Priced for a TAM, judged by a P&L

The bull math on Guardant is almost always TAM math. Tens of millions of unscreened average-risk Americans, a Medicare rate of $1,495 per Shield test, a first-mover blood-based franchise — multiply the addressable population by the reimbursement and the numbers become enormous. This is the cyclical-priced-as-secular problem in a new costume: the market capitalizes the largest plausible version of the opportunity and discounts the friction of actually capturing it.

The friction is everything. Reimbursement breadth beyond Medicare, physician ordering behavior, guideline inclusion that drives systematic adoption, competition that compresses pricing, and a clinical profile that limits Shield's role to a screening tier rather than the whole market — each of these stands between the TAM slide and the revenue line. Guardant's own 2026 screening guidance illustrates the gap honestly: it expects $162 million to $174 million of screening revenue from 210,000 to 225,000 Shield tests this year. That is a real, fast-growing business. It is also a small fraction of the implied TAM, and it is being valued as though the trajectory from here to full penetration is a foregone conclusion rather than a contested, capital-intensive, multi-year campaign against entrenched competitors.

The competition is not standing still

A first-mover advantage is only durable if the followers are slow or weak. Guardant's are neither. Exact Sciences is the incumbent in non-invasive colorectal screening, with Cologuard's installed base, payer relationships, primary-care distribution, and a next-generation Cologuard Plus that outperforms Shield on the precancerous-lesion detection that defines screening quality. Exact has spent years building exactly the commercial machine — the sales force, the prior-authorization workflows, the guideline relationships — that Guardant is now spending hundreds of millions of dollars a year to assemble from a smaller base.

And then there is Abbott, a diversified diagnostics giant with a balance sheet Guardant cannot approach, publicly working toward its own blood-based colorectal screening entry. When a profitable, deep-pocketed incumbent decides a category is worth entering, the economics for an unprofitable first mover deteriorate quickly: pricing comes under pressure, customer acquisition gets more expensive, and the window in which Shield is the only blood test in the room narrows. Guardant is trying to reach cash breakeven before that window closes. It is a race, and the company's persistent losses mean it is running it on borrowed money against opponents who are running it on their own.

Concentration and the policy dependency under the floor

There is a structural fragility worth naming. A large and growing share of Guardant's screening economics rests on a single reimbursement decision — the Medicare rate for Shield — and on the willingness of commercial payers to follow Medicare's lead. Reimbursement rates are administrative determinations, not market prices, and they can be revisited. A test priced and modeled on a $1,495 reimbursement is a test whose entire unit economics live or die by a number set by the Centers for Medicare & Medicaid Services and the coverage policies that ripple outward from it.

This is policy-dependence dressed as a moat. The bull case treats the Medicare rate as a settled foundation; a forensic reader treats it as an exposure. If reimbursement compresses, if commercial coverage lags, if guideline bodies hedge on blood-based screening as a primary modality, the per-test revenue that makes the TAM math work erodes — and it erodes against a cost base that has already been built out in anticipation of volume that may arrive more slowly and at lower prices than the model assumes.

The dilution flywheel

Tie the threads together and a pattern emerges that should worry anyone holding the equity at today's multiple. Guardant grows revenue impressively. The growth does not yet produce profit, so the company burns cash. The cash burn requires external financing, so the company raises equity and issues convertible debt. The new equity and the convertibles' eventual conversion expand the share count. The expanded share count raises the absolute level of profit the business must someday generate to justify any given per-share price. And so the bar moves higher even as the company runs faster toward it.

This is the dilution flywheel, and it is the quiet antagonist of every long-duration growth story that has not yet found its bottom-line inflection. It does not announce itself in the headline growth rate. It shows up slowly, in the footnotes, in the share count, in the convertible-note schedule, in the gap between revenue that crosses a billion dollars and a net loss that refuses to shrink. The flywheel is survivable — Guardant has access to capital, and the equity market has been generous — but it is not free, and the people paying for it are the existing shareholders whose claim on the eventual profits gets thinner with each turn.

What the bulls genuinely get right

It would be dishonest to leave the impression that Guardant is a hollow story, because in important respects it is not. The bulls are right about several things, and they are right with conviction.

They are right that the growth is genuinely broad-based. This is not one segment masking weakness elsewhere — oncology grew 36% on 47% volume growth, biopharma grew 17%, and screening grew more than 600%. All three engines are firing, and the 86,000 oncology tests in a single quarter reflect a Guardant360 franchise with durable, defensible demand from a clinical community that has integrated liquid biopsy into cancer care. That core oncology business is real, sticky, and growing.

They are right that Shield addresses a true unmet need. Roughly a third of eligible Americans are not screened for colorectal cancer at all, and the dominant reason is unwillingness to undergo a colonoscopy or complete a stool test. For that population, a simple blood draw is not a worse test than colonoscopy — it is infinitely better than the test they were never going to take. Compliance is the hidden variable in cancer screening, and a test patients will actually accept can save lives that a more sensitive test they refuse never will. The $1,495 Medicare rate, whatever its policy fragility, is a powerful unit economic if volume scales.

They are right that the cash burn is improving in the right direction. Full-year burn fell from $275 million in 2024 to $233 million in 2025, and management framed the year-over-year rise in first-quarter burn as driven largely by a one-time higher annual bonus payout — excluding which, the company says burn actually declined by $12 million. The balance sheet, freshly bolstered by over $700 million of capital, gives Guardant years of runway to prosecute the screening opportunity without an imminent funding cliff. And the raised full-year guidance — 32% to 34% implied growth — reflects management confidence backed by a quarter that genuinely beat on the top line.

A fair reading is that Guardant has a real franchise, a real product, and a real market. The disagreement is not about whether the business exists. It is about what it is worth, and when — if ever — the income statement catches up to the story.

The asymmetry of priced-for-perfection

Here is the structural problem with owning GH at a valuation built on the largest version of the screening opportunity: the risk is asymmetric, and it runs against the holder. When a stock is priced for a TAM it has not yet earned, the good outcomes are mostly already in the price and the bad outcomes are mostly not. If Shield penetration meets the bullish case, the upside is real but partly discounted. If reimbursement compresses, if Cologuard Plus and Abbott take share, if the precancerous-lesion gap caps Shield's clinical role, if the path to cash breakeven stretches another two or three years and demands another dilutive raise — any one of those, and certainly several together, forces a re-rating from a valuation that left little margin for disappointment.

That asymmetry is the whole trade. A profitable company growing 48% can absorb a stumble because its earnings provide a floor. A company losing $112 million a quarter has no such floor; its valuation is held up entirely by the market's continued willingness to believe the future justifies the present losses. Belief is a volatile collateral. The day the narrative cracks — a guidance trim, a reimbursement headline, a competitor's strong screening data — the same multiple that powered the stock up powers it down, and there are no current earnings to cushion the fall.

The kicker

Guardant Health is not a fraud and Shield is not a fiction; that is precisely what makes it dangerous, because the bull case is built on facts and the bear case is built on the same facts read forward instead of backward. The numbers everyone celebrates — 48% growth, six-hundred-percent screening gains, a billion in trailing revenue — are all true, and so is the $112 million quarterly loss they sit beside, and so is the $233 million of annual burn, and so is the $700 million of fresh capital raised to feed it, and so is the 13.2% advanced-adenoma sensitivity, and so is Abbott's coming entry. The art of reading a company like this is refusing to let the impressive true numbers crowd out the uncomfortable true numbers. Guardant is selling a screening franchise the market has already paid for; the only open question is whether the company can deliver the earnings before the bill for everyone else's money comes due.

The growth is real, the science is real, and the losses are real — and a stock priced for a screening empire it has not yet built is a bet that the first three reconcile before the cash and the patience of new investors run out.